{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-polycythemia+Vera+Myelofibrosis%28Post-PV+MF%29&page=2", "query": { "condition": "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-polycythemia+Vera+Myelofibrosis%28Post-PV+MF%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-10T13:48:48.332Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06327100", "title": "Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-Essential Thrombocytosis Myelofibrosis" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Tasquinimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-08-01", "completion_date": "2031-05-01", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06327100" }, { "nct_id": "NCT05280509", "title": "Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Primary Myelofibrosis", "Post-PV MF", "Post-ET Myelofibrosis" ], "interventions": [ { "name": "TL-895", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telios Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-06-09", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05280509" }, { "nct_id": "NCT03136185", "title": "Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Primary Myelofibrosis (PMF)" ], "interventions": [ { "name": "Bomedemstat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-07-18", "completion_date": "2022-03-08", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136185" }, { "nct_id": "NCT07357727", "title": "A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis (PMF)", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)" ], "interventions": [ { "name": "Pelabresib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 460, "start_date": "2026-05-27", "completion_date": "2030-12-27", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 1, "location_summary": "Berkeley Heights, New Jersey", "locations": [ { "city": "Berkeley Heights", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07357727" }, { "nct_id": "NCT01981850", "title": "A Phase 2 Study of RO7490677 In Participants With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Polycythemia Vera", "Post-Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "RO7490677", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2013-10-01", "completion_date": "2020-07-10", "has_results": true, "last_update_posted_date": "2022-01-05", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01981850" }, { "nct_id": "NCT01423851", "title": "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "NS-018", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NS Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2011-06", "completion_date": "2020-04-22", "has_results": true, "last_update_posted_date": "2022-03-09", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01423851" }, { "nct_id": "NCT06343805", "title": "A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Myelofibrosis", "Post-Essential Thrombocythemia Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "PMF", "PPV-MF", "PET-MF" ], "interventions": [ { "name": "AJ1-11095", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ajax Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2024-10-23", "completion_date": "2027-02-15", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 13, "location_summary": "Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06343805" }, { "nct_id": "NCT07362225", "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis，MF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes" ], "interventions": [], "intervention_types": [], "sponsor": "MPN Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-09-26", "completion_date": "2035-09-08", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362225" }, { "nct_id": "NCT04455841", "title": "INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anemia", "Post-essential Thrombocythemia Myelofibrosis", "Post-polycythemia Vera Myelofibrosis" ], "interventions": [ { "name": "INCB000928", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2021-03-19", "completion_date": "2027-11-26", "has_results": true, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 13, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04455841" }, { "nct_id": "NCT04676529", "title": "Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "PXS-5505", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Syntara", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2021-02-18", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-06-10T13:48:48.332Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04676529" } ] }